Baseline characteristics of patients randomized to receive maintenance therapy
| . | VT, n = 91 . | VP, n = 87 . | P . |
|---|---|---|---|
| Age, y | 71 (66-82) | 72 (65-84) | NS |
| Male, % | 53 | 47 | |
| IgG/IgA/light chain, % | 62/28/9 | 55/32/12 | NS |
| ISS stage I/II/III, % | 30/41/29 | 28/41/30 | NS |
| Mean creatinine, mg/dL | 1.02 | 1.0 | NS |
| Mean B2 microglobulin, mg/L | 3.7 | 3.8 | NS |
| Mean PCsBM infiltration, % | 38 | 44 | NS |
| Induction regimen, % | |||
| VMP | 52 | 51 | NS |
| VTP | 48 | 49 | NS |
| High-risk [t(4;14), t(14;16), del 17p] cytogenetic by FISH, % | 17 | 15 | NS |
| . | VT, n = 91 . | VP, n = 87 . | P . |
|---|---|---|---|
| Age, y | 71 (66-82) | 72 (65-84) | NS |
| Male, % | 53 | 47 | |
| IgG/IgA/light chain, % | 62/28/9 | 55/32/12 | NS |
| ISS stage I/II/III, % | 30/41/29 | 28/41/30 | NS |
| Mean creatinine, mg/dL | 1.02 | 1.0 | NS |
| Mean B2 microglobulin, mg/L | 3.7 | 3.8 | NS |
| Mean PCsBM infiltration, % | 38 | 44 | NS |
| Induction regimen, % | |||
| VMP | 52 | 51 | NS |
| VTP | 48 | 49 | NS |
| High-risk [t(4;14), t(14;16), del 17p] cytogenetic by FISH, % | 17 | 15 | NS |
Data are numbers (%) or means.
VT indicates bortezomib plus thalidomide; VP, bortezomib plus prednisone; ISS, International Staging System; PCsBM, plasma cell bone marrow infiltration; VMP, bortezomib plus melphalan and prednisone; VTP, bortezomib plus thalidomide and prednisone; and NS, not significant.